Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Two from OKC up for ‘Buzz of BIO’

Get in Touch

A pair of Oklahoma City-based companies have been selected as “Buzz of BIO” nominees for the 2014 Biotechnology Industry Organization annual convention. The annual  convention, which draws companies, scientists and economic development professionals from around the world, is June 23-26 in San Diego.

Cytovance Biologics, Inc., is nominated in the Pipelines of Promise category, while Caisson Biotech, LLC. is nominated in the Technologies of Tomorrow category. Voting continues through Tuesday, and winners will be recognized at the BIO show.

Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. Additionally, the company offers process development, cGMP cell banking and support services.

Three reason to vote for Cytovance:
1. Making a mark on biotech in Oklahoma City.
2. Incredible depth of scientific experience in a company of only 135 employees.
3. Cytovance is integral in converting today’s protein discoveries into future life-saving therapies.

Caisson Biotech has a patented heparosan-based drug delivery technology designed to improve the performance of drug compounds in terms of safety, tolerability, efficacy and quality. Caisson uses a novel, heparosan polymer that increases product half-life and stability and reduces immunogenicity.

Three reasons to vote for Caisson Biotech:
1. 2014 deal with Novo Nordisk ($167 M in milestone payments plus long-term residual royalties)
2. 2012 deal with Novo Nordisk ($100 M in milestone payments plus long-term residual royalties)
3. Technology opens new markets for existing drugs (re-tooling, drug enhancement & patent protection)

Click here to vote for the companies. Let’s get the vote out!

 

Author

  • admin admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E